Benzinga's Microcap Movers for Thursday July 12, 2012

Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:

Shares of Catalyst Pharmaceutical

, the Coral Gables, FL development-stage specialty pharmaceutical company, rose 21.89% Thursday on 7 times average volume. Catalyst Pharmaceutical announced Thursday that it expects to report top-line results from its CPP-109 (vigabatrin) Phase IIb trial around the end of September 2012 versus the previous guidance of early in the first quarter of 2013. After discussions with our collaborators, the National Institute on Drug Abuse and the Department of Veterans Affairs Cooperative Studies Program, and our statistical and regulatory consultants, we have been able to work through the complexities of modifying our statistical analysis plan. This will enable us to report top-line trial results about four months earlier than previously expected. "We are pleased that we will be able to report the top-line results of our CPP-109 Phase IIb clinical trial sooner than expected," said Patrick J. McEnany, Chief Executive Officer of Catalyst. "We are committed to bringing safe and effective breakthrough products for the treatment of cocaine addiction to the market as quickly as possible, and the earlier reporting of these data is consistent with that philosophy." Catalyst Pharmaceutical closed at $0.78 on Thursday.

Cereplast

, the El Segundo, CA bio-based resin developer, rose 20.30% Thursday on 5 times average volume. Cereplast announced Thursday that it has entered into a distribution agreement with Hamburg, Germany-based ALBIS PLASTIC GMBH to supply Cereplast bioplastic resins to the United Kingdom and Ireland. Cereplast has shipped the first purchase order to ALBIS PLASTIC, who will distribute both Cereplast Compostables resins, with an emphasis on blown film grades and blow molding grades, as well as Cereplast Sustainables resins, including the Cereplast Hybrid Resins product line. This contract signifies the growing demand in Europe for bioplastic resins, and expands Cereplast's foothold on the continent. "Cereplast offers an excellent range of sustainable plastics which complements Albis' extensive green portfolio perfectly," stated Ian Mills, managing director of Albis UK. Cereplast closed at $0.48 on Thursday.

Shares of NetSol Technologies

, the Calabasas, CA software company, rose 18.29% Thursday on 9 times average volume. NetSol Technologies today provided preliminary revenue and earnings per share results Thursday for the fiscal year and fourth quarter ended June 30, 2012. Preliminary revenue results indicate the company's strongest year ever, with consecutive sequential quarterly growth throughout, a company first, and the highest quarterly revenue in the company's history. Based on preliminary estimates, NetSol anticipates total revenue for the fiscal year will be in the range of $37 million to $38 million, indicating fiscal fourth quarter revenue of approximately $11.6 to $12.6 million, versus prior guidance of $8.6 million to $10.1 million. Previously, NetSol said that it expected total revenue for the fiscal year of approximately $34 million to $35.5 million, or revenue growth of 30% to 40% for the second half of the fiscal year compared with the first half of the year. Instead, the company now anticipates growth of 50% to 56% for the second half over the first half of the year. The company attributed the robust growth to having signed a number of new contracts in the fiscal fourth quarter and continued robust demand for its core NFS Suite offering. NetSol Technologies closed at $0.53 on Thursday.